Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Parkinson Disease 4, Autosomal Dominant Lewy Body 21Breast Neoplasms 17Neoplasms 16Multiple Myeloma 16Leukemia, Myeloid, Acute 15Recurrence 10Colorectal Neoplasms 10Myelodysplastic Syndromes 9Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Lymphoma, Follicular 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Stomach Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Purpura, Thrombocytopenic, Idiopathic 5Neoplasm Metastasis 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Graft vs Host Disease 5Esophageal Neoplasms 5Bronchiolitis Obliterans Syndrome 5Adenocarcinoma 5

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has announcements × Thyroid Carcinoma, Anaplastic × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡